Breaking News Instant updates and real-time market news.

DERM

Dermira

$5.71

-0.4 (-6.55%)

08:34
10/09/19
10/09
08:34
10/09/19
08:34

Dermira initiates dosing in Phase 3 lebrikizumab study

Dermira announced dosing of the first patient in a Phase 3 study evaluating the safety and efficacy of lebrikizumab in adult and adolescent patients ages 12 and older with moderate-to-severe atopic dermatitis, the most common form of eczema. Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with very high affinity, specifically preventing the formation of the IL-13Ra1/IL-4Ra heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology of atopic dermatitis by promoting type 2 inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening and infection.

DERM Dermira
$5.71

-0.4 (-6.55%)

03/27/19
HCWC
03/27/19
NO CHANGE
Target $22
HCWC
Buy
Dermira price target raised to $22 from $13 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised his price target for Dermira to $22 from $13 saying the company last week announced "very strong" data from the Phase 2B Treble study for lebrikizumab in the treatment of atopic dermatitis. The data arguably represents a "best case" scenario for Dermira, Tsao tells investors in a research note. The results were "sufficiently compelling to put to rest any debate" whether the company should move into lebrikizumab into Phase 3 testing, contends the analyst. He raised his peak sales estimate for lebrikizumab to $2.5B, up from $1.5B, and keeps a Buy rating on Dermira.
04/18/19
CANT
04/18/19
NO CHANGE
Target $25
CANT
Overweight
Dermira price target raised to $25 from $20 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target on Dermira to $25 as she is now including an estimate for sales for lebrikizumab following the positive Phase 2b data readout in atopic dermatitis. Chen keeps an Overweight rating on Dermira shares.
04/18/19
CANT
04/18/19
NO CHANGE
Target $25
CANT
Overweight
Cantor sees 'golden egg' potential in Dermira, boosts price target to $25
Cantor Fitzgerald analyst Louise Chen raised her price target for Dermira to $25 from $20 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 14c to $11.27. Peak sales potential of Qbrexza for hyperhidrosis and lebrikizumab for atopic dermatitis are underappreciated, Chen tells investors in a research note ahead of the long Easter weekend titled "We Think This Bunny Could Lay The Golden Egg." The analyst also thinks Dermira is an "interesting company in a consolidating space." Her new price target reflects the inclusion of Lebrikizumab sales following the positive Phase 2b data readout earlier this year.
06/06/19
MZHO
06/06/19
UPGRADE
Target $14
MZHO
Buy
Dermira upgraded to Buy from Neutral at Mizuho
Mizuho analyst Irina Koffler upgraded Dermira to Buy from Neutral while lowering her price target for the shares to $14 from $17. The analyst expects Almirall to exercise its European rights to lebrikizumab and she sees potential upside from other strategic alternatives. She attributes the 40% share selloff since April to financing uncertainty and the "lackluster" performance of Qbrexza. However, she views Dermira's risk/reward as favorable into Almirall's decision. The stock trades in-line with Koffler's $9 bear-case scenario, which assumes that Almirall opts out of the deal.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

09:24
10/14/19
10/14
09:24
10/14/19
09:24
Recommendations
Amazon.com analyst commentary  »

Loop Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

F

Ford

$8.78

0.145 (1.68%)

09:22
10/14/19
10/14
09:22
10/14/19
09:22
Hot Stocks
Ford reports Q3 Europe sales up 3.1% to 313,400 vehicles »

Ford sales grew more than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ACM

Aecom

$37.14

0.35 (0.95%)

, LPG

Dorian LPG

$11.48

0.22 (1.95%)

09:21
10/14/19
10/14
09:21
10/14/19
09:21
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: Aecom (ACM), up…

ACM

Aecom

$37.14

0.35 (0.95%)

LPG

Dorian LPG

$11.48

0.22 (1.95%)

LYFT

Lyft

$39.49

1.8 (4.78%)

WDC

Western Digital

$58.36

1.09 (1.90%)

FLXN

Flexion

$13.37

0.125 (0.94%)

AMTD

TD Ameritrade

$35.27

0.78 (2.26%)

IPGP

IPG Photonics

$136.12

6.24 (4.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

YNDX

Yandex

$29.95

-5.62 (-15.80%)

09:19
10/14/19
10/14
09:19
10/14/19
09:19
Recommendations
Yandex analyst commentary  »

Foreign ownership limit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

AMCX

AMC Networks

$48.42

0.89 (1.87%)

09:19
10/14/19
10/14
09:19
10/14/19
09:19
Downgrade
AMC Networks rating change  »

Evercore downgrades AMC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
10/14/19
10/14
09:18
10/14/19
09:18
Options
Overnight activity included 332 trades in SPX and 7 trades in VIX »

332 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

, ABBV

AbbVie

$73.66

1.39 (1.92%)

09:17
10/14/19
10/14
09:17
10/14/19
09:17
Hot Stocks
Allergan shareholders approve AbbVie acquisition proposal »

Allergan (AGN) announced…

AGN

Allergan

$169.06

1.255 (0.75%)

ABBV

AbbVie

$73.66

1.39 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TOL

Toll Brothers

$39.49

0.2 (0.51%)

09:16
10/14/19
10/14
09:16
10/14/19
09:16
Downgrade
Toll Brothers rating change  »

Toll Brothers downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBT

Global Blood Therapeutics

$46.49

0.61 (1.33%)

09:16
10/14/19
10/14
09:16
10/14/19
09:16
Recommendations
Global Blood Therapeutics analyst commentary  »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AMGN

Amgen

$200.76

2.05 (1.03%)

09:15
10/14/19
10/14
09:15
10/14/19
09:15
Initiation
Amgen initiated  »

Amgen resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

JAZZ

Jazz Pharmaceuticals

$118.61

0.62 (0.53%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Initiation
Jazz Pharmaceuticals initiated  »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBI

Pitney Bowes

$4.40

0.04 (0.92%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Hot Stocks
Pitney Bowes issues statement on malware attack »

Pitney Bowes issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

INFY

Infosys

$10.97

-0.22 (-1.97%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Downgrade
Infosys rating change  »

Infosys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

ARGO

Argo Group

$67.34

1.4 (2.12%)

09:12
10/14/19
10/14
09:12
10/14/19
09:12
Hot Stocks
Argo Group holder Voce comments on SEC probe »

Voce Capital, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARW

Arrow Electronics

$74.22

1.095 (1.50%)

, TXN

Texas Instruments

$130.08

2.52 (1.98%)

09:11
10/14/19
10/14
09:11
10/14/19
09:11
Recommendations
Arrow Electronics, Texas Instruments analyst commentary  »

Longbow says Arrow…

ARW

Arrow Electronics

$74.22

1.095 (1.50%)

TXN

Texas Instruments

$130.08

2.52 (1.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BKI

Black Knight

$61.68

0.39 (0.64%)

09:11
10/14/19
10/14
09:11
10/14/19
09:11
Hot Stocks
Black Knight receives to patents from USPTO »

Black Knight announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

UPS

UPS

$116.06

0.76 (0.66%)

09:10
10/14/19
10/14
09:10
10/14/19
09:10
Hot Stocks
UPS launches Storage on Demand service »

UPS announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

HON

Honeywell

$163.52

2.63 (1.63%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Hot Stocks
Honeywell finalizing new T55 engine to power U.S. Army's Chinook helicopters »

Honeywell is finalizing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

OKTA

Okta

$116.19

1.65 (1.44%)

, PING

Ping Identity

$16.47

0.45 (2.81%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Initiation
Okta, Ping Identity, Zscaler, Crowdstrike initiated  »

Citi expands Software…

OKTA

Okta

$116.19

1.65 (1.44%)

PING

Ping Identity

$16.47

0.45 (2.81%)

ZS

Zscaler

$48.16

0.81 (1.71%)

CRWD

Crowdstrike

$60.24

-1.08 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 19

    Nov

  • 12

    Dec

  • 16

    Dec

ERIC

Ericsson

$8.44

0.2 (2.43%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Hot Stocks
Ericsson and Watch Communications enter into partnership »

Watch Communications has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

OSTK

Overstock.com

$10.67

-0.18 (-1.66%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Hot Stocks
Medici Land Governance signs MOU with St. Kitts and Nevis government »

Overstock.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMTL

Comtech

$31.24

0.51 (1.66%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Hot Stocks
Comtech awarded $4.4M contract renewal »

Comtech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$95.80

9.86 (11.47%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Recommendations
Reata Pharmaceuticals analyst commentary  »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$20.76

0.76 (3.80%)

09:06
10/14/19
10/14
09:06
10/14/19
09:06
Recommendations
Wendy's analyst commentary  »

Wendy's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

  • 13

    Nov

LAND

Gladstone Land

$11.87

(0.00%)

09:06
10/14/19
10/14
09:06
10/14/19
09:06
Hot Stocks
Gladstone Land clarifies certain aspects of external fee structure »

Gladstone Land offered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.